Portal de Periódicos da CAPES

DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL

2017; Wiley; Volume: 35; Issue: S2 Linguagem: Inglês

10.1002/hon.2437_13

1099-1069

Ruth Pettengell, Rahman Uddin, Ariane Boumendil, Steve Robinson, Genea Smith, T Hawkins, Bernd Metzner, Marı́a Dolores Caballero, Hervé Tilly, Joanna Romejko‐Jarosińska, I. Bence‐Bruckler, Bik To, Carsten Utoft Niemann, Eva Kimby, Peter Dreger, Norbert Schmitz, A. H. Goldstone, Silvia Montoto,

CAR-T cell therapy research

Purpose: To evaluate the long- term effects of in vivo purging with rituximab 375 mg/m2 weekly x 4(RP) and maintenance rituximab 375 mg/m2 every 2 months for 4 doses (RM) on progression free survival (PFS) in patients with relapsed FL receiving a BEAM autograft (ASCT). Methods: 280 patents with relapsed FL after complete or very good partial remission after salvage chemotherapy were randomly assigned using a factorial design to rituximab (R) purging (RP; 375 mg/m2 once per week for 4 weeks) or observation (NP) before ASCT and to R maintenance (RM; 375 mg/m2 once every 2 months for 4 infusions) or observation (NM) (Pettengell et al. JCO 2014): there is thus a group of patients who received no R (neither for purging nor for maintenance) (no R) and a group who received R both for purging and maintenance (RR). Conclusion: The benefit of R maintenance after ASCT on PFS in patients with chemosensitive relapsed FL is sustained at 12 years, suggesting that RM adds to ASCT-mediated disease eradication and may enhance the curative potential of ASCT, as relapses were rare after 7.5 years. The success of salvage therapies at relapse post ASCT in rituximab naïve patients is reflected in comparable overall survival. Keywords: autologous stem cell transplantation (ASCT); follicular lymphoma (FL); rituximab.